At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Optical coherence tomography (OCT) (diagnostic test)
- How long the study runs
- Study runs about 65 months (dates as stated)
- About the drug or intervention
- Optical coherence tomography (OCT) — diagnostic test: Data of macular optical coherence tomography (OCT)
- Patient visit burden
- Not specified by the sponsor
In plain English
This study, run by the Institute of Molecular and Clinical Ophthalmology Basel, is looking at inherited retinal dystrophies, which are conditions that affect the light-sensitive tissue at the back of the eye. The study is about qualification for cone-optogenetics, an approach that may help vision. Not stated — ask the trial team about the full aims and how the treatment works.
Who can take part
- Patients: a diagnosis of a generalised inherited retinal disease (a condition affecting the retina that runs in families).
- Patients: low vision in the study eye, meaning eyesight at or worse than 0.05 (or 20/400) on a vision chart.
- Patients: able to have a macular optical coherence tomography (OCT) scan, which is a detailed picture of the central part of the retina.
- Healthy controls: normal findings on eye checks.
- Healthy controls: able to have a macular OCT scan.
Who may not be able to
- Anyone with other eye diseases that significantly affect eyesight or the structure of the retina.
- Anyone with a condition outside the eye that affects the retina, such as a neurodegenerative disease.
What taking part involves
- • Not stated — ask the trial team about what tests or procedures are involved.
Time commitment: Not stated — ask the trial team about visits, how long the study lasts, and what taking part involves.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- Not specified
- Who
- All
- Number of participants
- 1,000
- Started
- 2021-07-01
- Last checked
- 2025-07
Plain English Summary
What is this study?
- • Testing a new treatment for retinal dystrophies
- • Clinical study - 1,000 participants
- • This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration
Who can take part?
- • Adults
- • Diagnosed with retinal dystrophies
Where?
- • London - Moorfields Eye Hospital
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.
More detail
In a subset of patients with inherited retinal dystrophies (IRDs), cones lose their light-sensitive outer segments but remain alive in a dormant stage. This creates an opportunity to resensitize them through targeted optogenetic tools. However, the true proportion of low vision patients harboring dormant, non-functional cones, is currently unknown. The worldwide multicenter retrospective study (EyeConic) aims to estimate the proportion of low vision patients with remaining cone cell bodies for the first time.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: Not specified
- Who can join: All genders
What the study is looking for
- ✓Inclusion Criteria (patients):
- ✓Diagnosis of generalized IRD
- ✓Low vision as defined as visual acuity worse or equal to 0.05 (or 20/400) in the study eye
- ✓Availability of macular optical coherence tomography (OCT)
- ✓Inclusion Criteria (controls):
See the full criteria
Where Is This Study? (1 UK site)
Moorfields Eye Hospital
London, United Kingdom
How to Get in Touch
Lucas Janeschitz-Kriegl, MD
Sponsor contactCONTACT
Tiana Koottungal
Sponsor contactCONTACT